An Economic Analysis of Costs Associated with Development of a Cell Salvage Program by Waters, J.R. et al.
Cleveland State University
EngagedScholarship@CSU
Business Faculty Publications Monte Ahuja College of Business
2007
An Economic Analysis of Costs Associated with
Development of a Cell Salvage Program
J.R. Waters
Heidi H. Meier
Cleveland State University, h.meier@csuohio.edu
J.H. Waters
Follow this and additional works at: https://engagedscholarship.csuohio.edu/bus_facpub
Part of the Accounting Commons
How does access to this work benefit you? Let us know!
Publisher's Statement
This is a non-final version of an article published in final form in Waters, J. R., Meier, H. H., Waters, J.
H. (2007). ʺAn Economic Analysis of Costs Associated with Development of a Cell Salvage
Program.ʺ. Anesthesia & Analgesia, 104(4).
This Article is brought to you for free and open access by the Monte Ahuja College of Business at EngagedScholarship@CSU. It has been accepted for
inclusion in Business Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact
library.es@csuohio.edu.
Original Published Citation
Waters, J. R., Meier, H. H., Waters, J. H. (2007). An Economic Analysis of Costs Associated with Development of a Cell Salvage
Program. Anesthesia & Analgesia, 104(4), pp. 869-875.
An Economic Analysis of Costs Associated with
Development of a Cell Salvage Program
Janet Robinson Waters, MD,
MBA*
Heidi Hylton Meier, DBA, CPA*
Jonathan H. Waters, MD†
BACKGROUND: The increasing cost of blood products and associated risks of trans-
fusion have lead to a heightened interest in techniques which reduce or replace
allogeneic blood transfusion. The use of cell salvage is being explored in a number
of institutions. We present financial information which may be useful to institu-
tions that are considering the addition of a cell salvage service.
METHODS: A review of the cell salvage data from 2328 patients was used to estimate
the average cost of a packed red blood cell unit equivalent processed by cell salvage
equipment. In addition, an analysis was performed to assess the break-even point
of establishing a cell salvage service.
RESULTS: Initial capital outlay to establish a cell salvage service at this institution
was $103,551. The annual fixed operating cost was $250,943. The average cost of
transfusion of an allogeneic packed red blood cell unit was $200. For an equivalent
cell salvage unit, the cost was $89.46. The payback period was 1.9 mo.
CONCLUSION: This analysis suggests that cell salvage can be significantly less
expensive than allogeneic blood. The cost of cell salvage in other institutions will
vary depending upon case volume, expected levels of blood loss per case, and
initial investment costs. A step-by-step formula is provided to assist in the
evaluation of a cell salvage service in hospitals of various sizes.
Blood transfusion has been a vital element in the
success and progression of surgical treatment. The
cost of blood transfusion has soared during the past
decade from an average cost of $90.00 per packed red
blood cell (PRBC) unit in 1991 (1) to as much as
$300.00 per PRBC unit in 2000 (2). This increase is
borne by the hospitals where transfusions are given,
and has contributed significantly to the increase in
health care costs for the nation.
Multiple factors have contributed to the increasing
cost of blood transfusion. As our population ages, and as
surgical options expand, there is an increasing demand
for blood products (3). A continued increase in demand
is projected at 1% per year, putting pressure on the blood
banking community to increase donation rates (4). The
costs of collection, storage, and processing have in-
creased, and concerns of contamination with human
immunodeficiency virus and hepatitis have lead to more
stringent standards of testing (5,6).
The risks of transfusion are a concern to both the
public and the health care community. Blood-borne
transmission of acquired immune deficiency syndrome,
hepatitis, and other viral contaminants has been a subject
of media headlines for decades. Transfusion errors are a
significant cause of morbidity and mortality in blood
recipients. More recent studies indicate that blood trans-
fusions are associated with a higher incidence of post-
operative infection, fever and poor wound healing (7,8).
The complications of blood transfusion add to hospital
length of stay at rates as high as 1.3% per red blood cell
(RBC) unit transfused (9).
The rising costs and quality of care issues surround-
ing blood transfusion have led the medical commu-
nity to seek alternatives to blood transfusion in the
surgical setting. One of these alternatives involves the
use of a process called “cell salvage.” Cell salvage
involves suctioning blood from patients during surgi-
cal procedures, washing and filtering the blood, and
returning it to the patient. The goal of this study is to
assess the cost of the cell salvage process in a large
tertiary care hospital and to compare it with the cost of
standard transfusion.
METHODS
A cell salvage program was established at the Cleve-
land Clinic Foundation, Cleveland, OH. This program
conformed to the accreditation requirements of the
American Association of Blood Banks perioperative au-
tologous blood collection and administration standards
(10). In conjunction with these requirements, a database
was established which was used for collection of infor-
mation required for the cost assessment. Establishment
of the database for research use was approved by the
IRB.
Required Investment Capital
All expenditures necessary to establish a functional
autotransfusion service, including purchases of equip-
ment, supplies, and training of newly hired personnel
were assessed. The BRAT 2 Cell SalvageMachine (COBE
Cardiovascular, Arvada, CO) was selected. Other mod-
els are available and are priced comparably. Many
manufacturers offer lease programs, and some will sup-
ply machines free of charge if supplies are purchased at
a premium.
Annual Operating Costs
Direct costs are those which can be specifically traced
to an activity, department or product. Direct costs of cell
salvage include cost of labor, education, equipment, and
supplies. Direct costs may be fixed or variable. Fixed
costs will remain the same regardless of the number of
units produced, whereas variable costs will increase or
decrease with production rates. For example, the cost of
hiring three employees to provide basic cell salvage
services is a fixed cost. The annual salary of these
individuals will not change, assuming no overtime is
needed. The disposables used during cell salvage are a
variable cost. If only one patient per day receives cell
salvage services, only one set of disposables is used. If
five patients per day receive services, then five sets of
disposables will be used.
Indirect costs are those which cannot be traced di-
rectly to a process, department, or product. Examples in
the hospital setting include electricity, heat, and security
guards.
Direct Costs
Fixed expenses were established including labor,
continuous medical education, quality control, and
depreciation on equipment. The role of Medical Direc-
tor was held by a physician at a 0.2 full-time equivalent
level. This position is a requirement of the American
Association of Blood Banks Perioperative Accreditation
standards under which this program was modeled. It
was determined that a minimum of three technicians
was necessary to establish the service, one of whom
would serve as supervisor. Vacation pay, continuing
medical education time and benefits are included in
the assessment of labor costs. The schedule of the cell
salvage technicians allowed them to cover up to four
on-going cell salvage cases at a time, although excep-
tions to this schedule were made for open thoraco-
abdominal aneurysm repair, where the technician was
expected to stay in the operating room (OR) from the
time that the aortic crossclamp was placed to the time
that it was removed.
An assessment was made of the variable expenses
which occur during initial set up of equipment prior to
surgery, collection and transfusion of the first unit of
salvaged blood, and collection and transfusion of the
second and subsequent units of salvaged blood. As labor
is viewed as a fixed cost, there are no labor costs
included in the variable expenses. These expenses con-
sist primarily of testingmaterials and supplies needed to
perform cell salvage including disposables, medications,
and saline.
Indirect Costs
Indirect costs would include the electricity neces-
sary to operate the machines and space for the storage
of supplies and equipment. At the Cleveland Clinic
Foundation, these costs are difficult to assign directly.
Facilities where the cost structure differs from the
Cleveland Clinic facility may wish to consider indirect
costs in their own evaluations.
Unit Costs
Retrospective cell salvage case data from a 12-mo
period were collected from the database, which com-
prised information from 2328 patients, including data on
the number of units produced per case as well as a
hemoglobin value for each unit produced. Since the cell
salvage machine processes blood in batches dependent
upon the bowl size (135mL or 250mL) andwith varying
hemoglobins, it is difficult to draw a direct comparison
to a unit of allogeneic blood. For this reason, the volume
of blood returned to the patient was multiplied by the
hemoglobin of that unit in order to arrive at a red cell
mass. Previous investigators (11) have defined a unit of
allogeneic PRBCs as having a RBC mass of 200 mL. This
same definition was used for cell salvage. From these
2328 patients and their red cell mass calculations, a
frequency histogram was created. (Fig. 1), which was
Figure 1. This is a frequency histogram showing the number of
red blood cell units produced from cell salvage per surgical
procedure. Data from 2328 patients were used to develop the
histogram. Volume and hemoglobin of each processed unit
during these 2328 cases were used to establish a red blood cell
mass produced per case. A unit of packed red blood cells
(PRBC) has generally been defined to contain 200 mL of red
blood cell mass. The frequency histogram was generated from
the 2328 cases with red blood cell mass 200 mL being
considered to be 0 U produced; 200–400 mLwas considered to
be 1 U of PRBC equivalent; 400–600 mL was considered to be
2 U of PRBC equivalents, and so on.
used to establish the likely number of units produced
per case. This unit production of cases was applied to a
series of projected case numbers per year ranging from
500 cases to 5500 cases.
Break-Even Point
Unit costs for cell salvage blood were compared
with the purchase price of a unit of PRBCs supplied by
the American Red Cross. Standard transfusion incurs
blood banking costs, which can add approximately
$200.00 to the cost of each transfused unit. Since this is
largely a fixed cost, which is not significantly im-
pacted by the establishment of the autotransfusion
service, only the actual purchase price of PRBCs was
used as a comparison with the unit cost of salvaged
blood. The average cost savings was determined and
the number of cases required to cover the initial
capital investment was established.
RESULTS
Initial Outlay
The initial outlay required to establish a cell salvage
service at this institution was $103,551 (Table 1), which
included purchase of equipment, establishment of sup-
ply inventory, training time and materials for three
technicians. Annual fixed operating costs were $250,943
(Table 2), which includes labor, benefits, and vacation
time for three full-time technicians, and 20% of compen-
sation of a physician serving as Medical Director.
Break-Even Analysis
The break-even point will vary depending upon how
many cases are performed with the projected initial
investment. Using the distribution of units produced per
case as is shown in Figure 1, the projected cost per unit
of cell salvage blood was calculated (Table 3) as
$89.46/unit. The cost of purchased blood was $200.00
per RBC unit. Assuming that every cell salvage unit
would replace an allogeneic unit, the average savings
per unit was $110.54. To cover the initial investment, 403
cases would need to be performed.
Average Payback Period
Another measure that many organizations find
useful in evaluating large capital projects is the pay-
back period, which provides information on the
length of time, rather than the number of cases, which
are required for the organization to recoup its initial
Table 1. Initial Capital Investment
Equipment Price ($) Quantity
Capital
outlay ($)
COBE Brat 2 cell
salvage machine
17,000.00 5 85,000.00
Scales 15.00 5 75.00
HemaCuea 0.00 5 0.00
Intravenous poles 150.00 5 750.00
Message board 100.00 1 100.00
Training
Labor
Technician hours 27.13 320 8681.60
Supervisor hours 37.23 160 5956.80
Materials & supplies
for training







Suction tubing 12.00 1 12.00
Transfer bags 1.50 1 1.50
Sampling spikes 3.50 1 3.50
Filters 16.00 1 16.00
Investment in
inventory
Bowl pack, 250 mL 60.00 10 600.00
Bowl pack, 135 mL 60.00 10 600.00
Reservoirs 25.00 10 250.00
Suction lines 12.00 20 240.00
Collection bags 1.50 30 45.00
Saline, 3000 mL 3.00 30 90.00
Saline, 1000 mL 1.00 50 50.00
Heparin, 10,000 u in
10 mL
1.00 75 75.00
Heparin, 10,000 u in
1 mL
1.00 125 125.00
Heparin, 20,000 u in
10 mL
1.00 125 125.00
Cuvettes 0.50 100 50.00
Sampling spikes 3.50 30 105.00




a Machines provided free of charge by manufacturer of disposables.
Table 2. Annual Operating Costs
Fixed expenses
Labor
Physician (20 percent FTE) $64,000
Supervising technician (1 FTE) $70,000
Technicians (2 FTE) $102,000
Depreciation on equipment $12,143
Quality control program $2,800
Fixed operating costs $250,943













Zero units 482 0 204.88 98,844.26
One unit 745 745 204.88 152,531.08
Two units 442 884 206.88 91,413.86
Three units 252 757 208.88 52,677.26
Four units 200 798 210.88 42,083.18
Five units 104 521 212.88 22,174.89
Six units 82 493 214.88 17,670.96
Seven units 66 461 216.88 14,268.35
Eight units 50 404 218.88 11,039.62
Nine units 19 168 220.88 4,117.15
Ten plus
units
58 581 222.88 12,952.51
Total 2500 5810 $519,773.10
Average Cost per Unit  Total cost/Units produced  $519,773.10/5810  $89.46 per
unit.
investment. With the initial capital investment and an
annual case rate of 2500 cases, the payback period
would be 1.93 mo.
Variable Annual Case Volume
Since the payback period and break-even point are
dependent upon the number of cases performed per
year, calculations were performed with a range of 500
to 5500 cases per year (Table 4). Based upon the annual
fixed operating costs of $250,943, the fixed cost per
case ranges from $45.63 to $501.89 for 5500–500 cases
per year, respectively. The variable cost of equipment
set up, testing and supplies is $104.50 per case. The total
cost of cell salvage processing, including fixed and
variable expenses is $150.13 if 5500 cases are performed
per year but $606.39 if only 500 cases are performed. As
can be seen in Table 4, the number of cases required to
break even varies considerably, dependent upon the
number of cases performed per year.
In the Appendix, an outline is provided for how
any hospital might calculate their own break-even
point.
DISCUSSIONS
At a production rate of 2500 cases, the cost to
provide a technician and a cell salvage machine was
$204.88 per case, which was very comparable to the
$200.00 acquisition cost of a unit of allogeneic PRBC.
On average, this cell salvage service produced 2.3 U of
blood per case. When a unit-to-unit comparison was
made, the cost per RBC unit of cell salvage blood was
$89.46. For this hospital, the cost of a cell salvage unit
was less than that of an allogeneic unit. Assuming that
every cell salvage unit replaced an allogeneic unit, the
payback period for setting up the program was slightly
short of 2 mo.
The applicability of this analysis to other institu-
tions will vary, depending upon the choice of equip-
ment, the type of manpower coverage desired, and the
cost that the institution pays for allogeneic blood. A
very conservative estimate of $200 for allogeneic blood
was used for comparison. The economic imperative of
this service becomes much greater as this price
increases.
Equipment costs can also vary the results of this
analysis. The BRAT 2 Cell Salvage Machine was
selected by the studied institution because of its ability
to process blood rapidly. This rapid processing was
important when performing thoraco-abdominal aneu-
rysm repair, which was a common procedure at this
facility. Other cell salvage machines can be obtained at
comparable or less cost but speed of processing may be
sacrificed. How the equipment is paid for is also vari-
able. It can be purchased outright or the machines can be
obtained through a lease program, which would reduce
the initial start up investment, although the cost of the
machine ultimately gets bundled into the supplies, in-
creasing the variable cost of the technology.
The manner in which the equipment is set up and
operated will also vary the results of the analysis.
Manpower options would include restricting the
availability of this service to specific hours of the day,
rather than providing 24 h a day, 7 day a week
coverage. An alternative would include using person-
nel who are already part of the OR team, including the
anesthesiologist, a circulating nurse or a perfusionist.
If this choice is made, extensive training should be
given to these individuals in order to avoid significant
risks of error and loss of efficiency. It is important to
note that for the purposes of this analysis, other
services provided by the cell salvage program techni-
cians were not included in these calculations. These
services included the provision of normovolemic he-
modilution, occasional perioperative apheresis, and
platelet gel production. In addition, the technicians
periodically provided point-of-care laboratory testing
for the anesthesiologist managing the transfusion
decisions.
A question arises as to the number of hospitals to
which this analysis might be applicable. The number
of ORs and the complexity of the cases performed
could affect the number of cell salvage cases, which
could be performed on any given day. The Cleveland
Clinic Foundation has reported to the National Center




























5500 45.63 104.50 150.13 65.90 134.10 1,714,150.75 0.72 332
5000 50.19 104.50 154.69 67.86 132.14 1,535,506.11 0.81 337
4500 55.77 104.50 160.27 70.26 129.74 1,356,861.46 0.92 343
4000 62.74 104.50 167.24 73.26 126.74 1,178,216.81 1.05 351
3500 71.70 104.50 176.20 77.12 122.88 999,572.17 1.24 362
3000 83.65 104.50 188.15 82.26 117.74 820,927.52 1.51 378
2500 100.38 104.50 204.88 89.46 110.54 642,282.88 1.93 403
2000 125.47 104.50 229.97 100.25 99.75 463,638.23 2.68 446
1500 167.30 104.50 271.80 118.25 81.75 284,993.58 4.36 545
1000 250.94 104.50 355.44 154.24 45.76 106,348.94 11.68 974
500 501.89 104.50 606.39 262.21 62.21 72,295.71 17.19 N/A
for Health Statistics that it is a 1032 bed facility. For
comparison purposes, NY Presbyterian Hospital re-
ports 2095 beds, Thomas Jefferson in Philadelphia
reports 905, the University of Pittsburgh’s Presbyte-
rian Hospital reports 1412 (12). According to the
National Center for Health Statistics, there were 256
hospitals in 2003 with more than 500 beds, of which
the Cleveland Clinic would be very representative.
Thus, the performance of 2500 cell salvage cases in a
given year should be generalizable to this group of
large, tertiary care hospitals where the opportunity for
allogeneic avoidance is greatest. A search of the
Healthcare Cost and Utilization Project database re-
veals that 63% of RBC transfusions in 2003 occurred in
these large hospitals,1 which suggests that the imple-
mentation of cell salvage programs in this cohort of
large hospitals could significantly impact the avail-
ability and cost of blood in the United States.
To take full advantage of cell salvage, every effort
should be made to increase the number of units pro-
duced per case. In general, the more units produced per
case decreases the cost per RBC unit. Optimization of
blood collection and return can be done in a number of
ways. First, a critical evaluation of the indications for
applying this technology is required. In general, cardiac
surgery, major vascular surgery, and liver transplanta-
tion would comprise the primary indications. There are
many other indications but each institution should de-
termine their own indications because blood loss varies
dependent upon individual surgeon skill, and the blood
volume of the patient population served. In addition to
appropriate indications, all lost blood should be cap-
tured and returned whenever possible. This can be done
by minimizing suction forces applied to the shed blood
(13,14) and by rinsing laparotomy sponges that have
been soaked with blood (15). Maximizing the number of
units produced per case effectively reduces the unit cost
of cell salvage blood.
Though not incorporated into this analysis, the cost
of the cell salvage system can be reduced through the
use of a standby system, in which only collection takes
place without processing. If enough blood is collected,
then the disposables necessary to perform the washing
are set-up, thus reducing the cost of providing cell
salvage by two-thirds if no blood is processed. In the
distribution of cases shown in the frequency histo-
gram, 19% of the cases were reported as having
resulted in no blood return. It is important to reiterate
that for the purposes of our calculations, 0–200 mL of
RBC mass was defined as “0” U, 200–400 mL as 1 U,
etc. Thus, for the cases where “0” units were reported,
blood may have actually been processed and returned.
Because of the standby system and the way that PRBC
equivalent was calculated, the cost per RBC unit may
have been less than what was reported here.
A factor beyond the scope of this analysis is the
complication of cell salvage and allogeneic blood. This
was omitted for two primary reasons. First, the com-
plications of allogeneic blood are not agreed upon,
change from year to year, and the extent of these
complications is not fully recognized nor agreed upon.
Second, cell salvage blood has well-known complica-
tions, but their variety and severity can be eliminated
or significantly reduced with a quality program,
which follows the American Association of Blood
Banks’ perioperative standards.
Another factor not accounted for in this comparison
was the quality of blood obtained. It would be difficult
to evaluate this quality, although comparison might
be implied through a number of surrogate measures.
First, cell salvage blood maintains normal intracellular
2,3-DPG and ATP levels, whereas stored blood does
not (16,17). Therefore, some assumption can be made
that oxygen delivery would be better with the cell
salvage product. Cell salvage blood maintains the
normal biconcave disk shape (18); whereas allogeneic
blood assumes an echinocyte shape after about 14
days (19)—a change thought to impair its ability to
traverse the capillary bed (20). For allogeneic blood,
this storage defect has been associated with worsened
outcomes (21). Cell salvage blood maintains normal
osmotic fragility, whereas, allogeneic stored blood
does not. Cell salvage RBC survival in circulation is no
different than if it had not been washed (22), whereas,
allogeneic blood ages while in storage. Activated
complement and elastase (23) concentrations are nor-
mal or subnormal in cell salvage blood, whereas they
are increased in stored allogeneic blood (24,25). These
surrogate data would suggest that a patient is better
off with their own, washed blood instead of a stored,
allogeneic unit. Outcome comparisons of these tech-
niques have yet to be performed.
Only two other economic analyses of cell salvage
have been published. In Szpisjak et al.’s (26) work,
economic modeling was used to determine whether it
was more effective for a hospital to outsource a cell
salvage service or to perform the service in-house. It
was determined that in-house management of a cell
salvage program only became more cost-effective than
outsourcing when more than 110 cases/year were
performed. In a different study evaluating cost effec-
tiveness of cell salvage in liver transplantation, cell
salvage use provided a 26% reduction in cost when
compared to allogeneic transfusion (27). Although
these studies addressed very different issues than this
study, the findings among the three are compatible.
In conclusion, this analysis indicates that the imple-
mentation of a cell salvage program can be cost
favorable for a large, tertiary care hospital. Benefits to
the patient, such as avoidance of blood borne disease,
a decreased chance of postoperative infection and a
shortened hospital stay may further add to the eco-
nomic benefit of this technology. Any hospital, which
performs surgery with significant blood loss, may
1http://hcup.ahrq.gov/hcup.net, search terms: ICD-9 code
99.04.
wish to consider the introduction of cell salvage
services. An Appendix is attached which might help
other hospitals calculate their own cost of cell salvage.
APPENDIX
Break-even analysis may be estimated for any in-
stitution by taking the following steps:
1. Determine the number of patients likely to benefit
from cell salvage services. Patients undergoing
procedures associated with high blood loss will
benefit most. A review of transfusion records for
high blood loss surgical procedures will provide
useful information in making this determination.
Estimate the number of cases likely to use cell
salvage at your facility if the service were to
become available.
2. Estimate the probable transfusion needs of your surgical
patient population using retrospective data. Build a
table similar to Table 4. Insert information based
upon past transfusions performed on the selected
patient population. Calculate the number of pa-
tients likely to receive 1 U, 2 U, 3 U, etc. Estimate
the costs of cell salvage in each scenario.
3. Determine the start-up costs. This will include
equipment if purchased, initial purchase of sup-
plies, training, etc.
4. Determine the annual fixed operating costs. The
fixed operating costs will include labor, benefits,
continuing medical education, and equipment
rental should it be determined to lease rather
than buy the equipment.
5. Compute the fixed production costs per case.
Fixed production cost per case  Fixed annual
operating costs/Expected annual case number.
6. Determine the variable production cost of the
first unit of salvaged blood. This will include the
set-up costs, tests, disposables, etc.
7. Calculate the total production cost for the first
salvaged unit. Fixed production cost per case 
Variable production cost for 1st unit  Total
production cost for 1st unit produced.
8. Calculate the costs associated with the second
and subsequent units produced.
9. Determine the average unit cost of cell salvage.
Average unit cost of cell salvage blood  Total
cost of cell salvage service/Units produced by
cell salvage service Determine what savings
would be incurred by a cell salvage service.
10. Subtract the average unit cost of cell salvage
from the unit cost of allogeneic transfusion at
your facility. Unit cost of allogeneic transfu-
sion  Average unit cost of cell salvage unit 
Savings per unit.
11. Determine the number of cell salvage cases needed to
recover start-up costs. Divide the total cost of cell
salvage by the unit savings of cell salvage to
determine the number of cases required to reach
your break-even point. Number of cell salvage
cases needed to recover start-up costs  Total
costs of cell salvage/Unit savings of cell salvage.
12. Determine the break-even point. Estimate how
many months are likely to pass before comple-
tion of the number of cell salvage cases required
to recover start-up costs.
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